GSK BHR Study (Sont)

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• Asthma diagnosis

• Controller medications or moderate inhaled corticosteroid dose

• Evidence of reversibility

Exclusion Criteria:

• Life-threatening asthma

• Asthma instability

• Concurrent respiratory disease

• Drug allergy

• Respiratory tract infection

• Systemic corticosteroid use

• Immunosuppressive medication use

• Positive pregnancy test

• Tobacco use

• Site affiliation